{"@context":{"ns0":"http://www.ebi.ac.uk/efo/","rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","owl":"http://www.w3.org/2002/07/owl#","rdfs":"http://www.w3.org/2000/01/rdf-schema#","obo_purl":"http://purl.obolibrary.org/obo/","metadata_def":"http://data.bioontology.org/metadata/def/","metadata":"http://data.bioontology.org/metadata/"},"@graph":[{"@id":"ns0:EFO_0005127","@type":"owl:Class","rdfs:subClassOf":{"@id":"ns0:EFO_0001444"},"rdfs:label":"cancer biomarker measurement","obo_purl:IAO_0000115":"cancer biomarkers, such as cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein, are used as indicators for cancer screening and as predictors for therapeutic responses and prognoses in cancer patient","obo_purl:IAO_0000117":"Dani Welter","ns0:gwas_trait":{"@type":"http://www.w3.org/2001/XMLSchema#boolean","@value":"1"},"metadata:def/prefLabel":"cancer biomarker measurement","metadata:def/mappingLoom":"cancerbiomarkermeasurement","metadata:def/mappingSameURI":{"@id":"ns0:EFO_0005127"},"metadata:prefixIRI":"efo:EFO_0005127"},{"@id":"ns0:EFO_0004626","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0004627","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0004739","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0005132","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0005187","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0010244","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0010583","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0010584","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0010585","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0010603","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0020994","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}},{"@id":"ns0:EFO_0020995","rdfs:subClassOf":{"@id":"ns0:EFO_0005127"}}]}